Title: A Phase I/II Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus CTLA-4 Blockade in Advanced Melanoma (Mel62; 6PAC)1

Principal Investigator: Elizabeth Gaughan, MD, University of Virginia

Study Director: Craig L. Slingluff, Jr, MD, University of Virginia

Continue Reading

Description: For this single-arm, open-table, phase 1/2 trial (ClinicalTrials.gov Identifier: NCT02385669), researchers are evaluating whether 6MHP, a peptide vaccine, is safe and efficacious when combined with ipilimumab in patients with stage IIIB or higher melanoma.

6MHP is made up of 6 peptides from melanoma proteins. The vaccine will be delivered intradermally and subcutaneously alongside ipilimumab 3 mg/kg once per 21 days.

The primary endpoints are safety, CD4+ T cell responses, and disease control rate.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02385669.

Status: This study is open and recruiting patients as of August 11, 2017.

This study is sponsored by Craig L Slingluff, Jr.

Reference

  1. Clinicaltrials.gov. A phase I/II trial to evaluate a peptide vaccine plus ipilimumab in patients with melanoma (Mel62; 6PAC).  NCT02385669. https://clinicaltrials.gov/ct2/show/NCT02385669. Accessed August 11, 2017.

Topics:

Melanoma Skin Cancer